JPWO2016133036A1 - Fatigue improver - Google Patents
Fatigue improver Download PDFInfo
- Publication number
- JPWO2016133036A1 JPWO2016133036A1 JP2017500660A JP2017500660A JPWO2016133036A1 JP WO2016133036 A1 JPWO2016133036 A1 JP WO2016133036A1 JP 2017500660 A JP2017500660 A JP 2017500660A JP 2017500660 A JP2017500660 A JP 2017500660A JP WO2016133036 A1 JPWO2016133036 A1 JP WO2016133036A1
- Authority
- JP
- Japan
- Prior art keywords
- protein
- fatigue
- milk
- casein
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims abstract description 146
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 85
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 85
- 102000011632 Caseins Human genes 0.000 claims abstract description 82
- 108010076119 Caseins Proteins 0.000 claims abstract description 82
- 235000021119 whey protein Nutrition 0.000 claims abstract description 80
- 102000014171 Milk Proteins Human genes 0.000 claims abstract description 78
- 108010011756 Milk Proteins Proteins 0.000 claims abstract description 78
- 235000021239 milk protein Nutrition 0.000 claims abstract description 78
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 68
- 239000007788 liquid Substances 0.000 claims abstract description 65
- 235000018102 proteins Nutrition 0.000 claims abstract description 51
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 51
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 51
- 235000013365 dairy product Nutrition 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 230000037396 body weight Effects 0.000 claims description 27
- 235000013305 food Nutrition 0.000 claims description 27
- 230000006872 improvement Effects 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 238000004806 packaging method and process Methods 0.000 claims description 18
- 235000012054 meals Nutrition 0.000 claims description 16
- 230000002929 anti-fatigue Effects 0.000 claims 1
- 235000013336 milk Nutrition 0.000 abstract description 31
- 239000008267 milk Substances 0.000 abstract description 31
- 210000004080 milk Anatomy 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 26
- 230000037406 food intake Effects 0.000 abstract description 11
- 239000005018 casein Substances 0.000 abstract description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract description 2
- 235000021240 caseins Nutrition 0.000 abstract description 2
- 239000002608 ionic liquid Substances 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 description 29
- 238000004659 sterilization and disinfection Methods 0.000 description 28
- 239000012141 concentrate Substances 0.000 description 10
- 239000002994 raw material Substances 0.000 description 9
- 230000036541 health Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 244000257790 Brassica carinata Species 0.000 description 6
- 235000005156 Brassica carinata Nutrition 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 239000005862 Whey Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 4
- -1 etc.) Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000021243 milk fat Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000000386 athletic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 235000020185 raw untreated milk Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000007696 Kjeldahl method Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010065713 Gastric Fistula Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 235000021156 lunch Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 235000020200 pasteurised milk Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 235000014059 processed cheese Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本発明は、多量かつ長期間の液体の摂取を必要とせず、摂取すること自体が負担とならない疲労改善剤を提供することを目的とし、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を含む乳性液状組成物を有効成分として含んでなる疲労改善剤であって、乳性液状組成物における乳タンパク質混合物の濃度が４〜８重量％であり、かつホエイタンパク質に対するカゼインタンパク質のタンパク質量比（カゼインタンパク質／ホエイタンパク質）が２〜２０である疲労改善剤を提供する。この疲労改善剤は、例えば、１日あたり１００〜５００ｍｌ、２〜８週間の摂取で疲労改善の効果を奏する。The present invention aims to provide a fatigue-improving agent that does not require ingestion of a large amount of liquid for a long period of time, and ingestion itself is not a burden, and milk comprising a milk protein mixture containing casein protein and whey protein A fatigue-improving agent comprising an ionic liquid composition as an active ingredient, wherein the concentration of the milk protein mixture in the dairy liquid composition is 4 to 8% by weight, and the protein amount ratio of casein protein to whey protein (casein) The present invention provides a fatigue ameliorating agent having a protein / whey protein ratio of 2-20. This fatigue-improving agent, for example, exhibits an effect of improving fatigue when taken for 100 to 500 ml per day for 2 to 8 weeks.
Description
本発明は、疲労改善剤に関する。 The present invention relates to a fatigue improving agent.
近年、健康増進を目的として、タンパク質を主成分とする栄養補助剤（サプリメント）を経口摂取して、運動する者（対象）は多い。このような栄養補助剤として、プロテイン粉末があり、その主成分として、牛乳を原料とするホエイタンパク質（乳清タンパク質）およびカゼインタンパク質が知られている。 In recent years, there are many people (subjects) who exercise by taking a nutritional supplement (supplement) mainly composed of protein for the purpose of promoting health. As such a nutritional supplement, there is protein powder, and as its main component, whey protein (whey protein) and casein protein made from milk are known.
また、牛乳は、学校給食などで定番であり、老若男女を問わず、飲用習慣を有し、牛乳を原料とするホエイタンパク質（乳清タンパク質）およびカゼインタンパク質を手軽に補給できる媒体である。さらに、牛乳は朝食の一品などで日常の食生活で採り入れられるなど、飲用する機会が多い。 Milk is a standard in school lunches, and is a medium that can be easily replenished with whey protein (whey protein) and casein protein using milk as a raw material, regardless of age or sex. In addition, there are many opportunities to drink milk, such as being picked up in daily eating habits as a breakfast item.
牛乳には、各種の健康機能が知られており、その中には、疲労改善の効果も知られている。非特許文献１では、社会人アメリカンフットボール男性選手（２６．９±３．２歳）３８名で、シーズン開始からトレーニング期間の１６週間にわたり毎日牛乳を５００ｍｌ、さらに週３回のトレーニング直後に毎回５００ｍｌを加えて牛乳を摂取し、栄養指導を行った牛乳介入群と、牛乳を摂取しなかった対照群とで比較観察をしたところ、牛乳介入群では、トレーニング後の自覚疲労も抑制される傾向にあり、対照群では、トレーニング後の疲労度の変化が観察されなかったことが記載されている（非特許文献１）。 Various health functions are known for milk, and the effect of improving fatigue is also known among them. According to Non-Patent Document 1, 38 American football male players (26.9 ± 3.2 years old), 500 ml of milk every day for 16 weeks from the start of the season to the training period, and 500 ml each time immediately after training 3 times a week In comparison with the milk intervention group that received milk and fed nutritional guidance and the control group that did not receive milk, the milk intervention group tended to suppress subjective fatigue after training. In the control group, it is described that no change in the fatigue level after training was observed (Non-Patent Document 1).
非特許文献１では、１日の牛乳の摂取量が５００ｍｌ〜１０００ｍｌとなり、コップ１杯が１００ｍｌ〜２００ｍｌであることを鑑みれば、１日にコップ２．５〜１０杯を飲用することになり、多量の摂取を必要とする。このような多量の牛乳の摂取は、時として、エネルギーを多量に摂取できない乳幼児や高齢者には、その摂取自体が困難となり、一方で、スポーツ選手ほど運動による多大なエネルギー（カロリー）の消費が期待できないスポーツ愛好家、および／または運動習慣のない者にとっては、摂取エネルギーの過多に伴う、肥満を始めとする生活習慣病の発症の懸念もある。また、年齢を問わず、１日にコップ数杯の牛乳を摂取すること自体が負担となることも考えられる。特に運動直後は、筋肉合成を速やかに促進させる必要があるのにも関わらず、運動によるホルモン分泌作用によって食欲が減退するため、多量の乳タンパク質の摂取が負担となることが考えられる。 In Non-Patent Document 1, in view of the fact that the daily milk intake is 500 ml to 1000 ml, and one cup is 100 ml to 200 ml, 2.5 to 10 cups will be drunk per day. Requires large intake. Ingestion of such a large amount of milk sometimes makes it difficult for infants and the elderly who cannot take in a large amount of energy, but on the other hand, sports athletes consume more energy (calorie) due to exercise. For sports enthusiasts who cannot be expected and / or those who do not have exercise habits, there are also concerns about development of lifestyle-related diseases such as obesity due to excessive intake of energy. In addition, taking a few cups of milk a day can be a burden, regardless of age. In particular, immediately after exercise, although it is necessary to promptly promote muscle synthesis, the appetite is reduced due to hormone secretion by exercise, so that it is considered that a large amount of milk protein intake becomes a burden.
一方、非特許文献１のような１日５００ｍｌ〜１０００ｍｌの牛乳を１６週間摂取という、多量かつ長期間の液体の摂取を必要としない疲労改善剤はこれまで知られていない。そこで、このような効果を奏する、新たな疲労改善剤を提供することが課題であった。 On the other hand, there has not been known a fatigue ameliorating agent that does not require intake of a large amount of liquid for a long period of time, such as non-patent document 1, in which milk of 500 ml to 1000 ml per day is ingested for 16 weeks. Therefore, it has been a problem to provide a new fatigue improving agent that exhibits such effects.
本発明者らは、前記課題を解決すべく鋭意研究を重ねた結果、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を含む乳性液状組成物を有効成分として含んでなる疲労改善剤であって、乳性液状組成物における乳タンパク質混合物の濃度が４〜８重量％であり、かつホエイタンパク質に対するカゼインタンパク質のタンパク質量比（カゼインタンパク質／ホエイタンパク質）が２〜２０である疲労改善剤を見出した。 As a result of intensive research to solve the above-mentioned problems, the present inventors are a fatigue improving agent comprising a milky liquid composition containing a milk protein mixture containing casein protein and whey protein as an active ingredient. The present invention has found a fatigue-improving agent having a milk protein mixture concentration of 4 to 8% by weight in a milky liquid composition and a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20. .
また、本発明者らは、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を含む乳性液状組成物を有効成分として含んでなる疲労改善剤であって、乳性液状組成物における乳タンパク質混合物の濃度が４〜８重量％であり、かつホエイタンパク質に対するカゼインタンパク質のタンパク質量比（カゼインタンパク質／ホエイタンパク質）が２〜２０である疲労改善剤を、１日あたり１００〜５００ｍｌ、２〜８週間の摂取で疲労改善の効果を奏することを見出した。すなわち、本発明の疲労改善剤は、従来の、非特許文献１のような、１日５００ｍｌ〜１０００ｍｌの牛乳（カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を３．６重量％含有する乳性液状組成物ともいえる）の１６週間摂取という、多量かつ長期間の液体の摂取を必要とせず、手軽に効率よく疲労改善効果が得られることも見出した。 The present inventors also provide a fatigue reducing agent comprising a milky liquid composition containing a milk protein mixture containing casein protein and whey protein as an active ingredient, wherein the milk protein mixture in the milky liquid composition A fatigue-improving agent having a concentration of 4 to 8% by weight and a casein protein to whey protein ratio (casein protein / whey protein) of 2 to 20 is 100 to 500 ml per day for 2 to 8 weeks. It was found that taking it has an effect of improving fatigue. That is, the fatigue ameliorating agent of the present invention, as in Non-Patent Document 1, is 500 ml to 1000 ml of milk (3.6% by weight of milk protein mixture containing casein protein and whey protein per day). It was also found that the effect of improving fatigue can be obtained easily and efficiently without the need for large-volume and long-term liquid intake, which can be said to be a liquid composition for 16 weeks.
すなわち、本発明は、次の通りとなる。
［１］カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を含む乳性液状組成物を有効成分として含んでなる疲労改善剤であって、乳性液状組成物における乳タンパク質混合物の濃度が４〜８重量％であり、かつホエイタンパク質に対するカゼインタンパク質のタンパク質量比（カゼインタンパク質／ホエイタンパク質）が２〜２０である疲労改善剤、
［２］乳タンパク質混合物が総タンパク質量で一日あたり０．０６ｇ／ｋｇ体重以上となるように摂取される、［１］に記載の疲労改善剤、
［３］１〜８週間継続して摂取されることを特徴とする、［１］または［２］に記載の疲労改善剤、
［４］一食あたりの単位包装形態からなり、該単位包装形態中に、乳タンパク質混合物を一食摂取量として総タンパク質量で３ｇ以上含む、［１］〜［３］のいずれか１に記載の疲労改善剤、
［５］運動する対象により摂取される、［１］〜［４］のいずれか１に記載の疲労改善剤、
［６］のカゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を含む乳性液状組成物を対象に摂取させる工程を含み、乳性液状組成物において、乳タンパク質混合物の濃度が４〜８重量％であり、かつホエイタンパク質に対するカゼインタンパク質のタンパク質量比（カゼインタンパク質／ホエイタンパク質）が２〜２０である疲労改善方法（ヒトに対する医療行為を除く）、
［７］乳タンパク質混合物が総タンパク質量で一日あたり０．０６ｇ／ｋｇ体重以上となるように摂取される、［６］に記載の疲労改善方法、
［８］１〜８週間継続して摂取させることを特徴とする、［６］または［７］に記載の疲労改善方法、
［９］乳性液状組成物は、一食あたりの単位包装形態からなり、該単位包装形態中に、乳タンパク質混合物を一食摂取量として総タンパク質量で３ｇ以上含む、［６］〜［８］のいずれか１に記載の疲労改善方法、
［１０］運動する対象に摂取させる、［６］〜［９］のいずれか１に記載の疲労改善方法、
［１１］カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を含む乳性液状組成物を有効成分として含んでなる疲労改善用食品組成物であって、前記乳性液状組成物における前記乳タンパク質混合物の濃度が４〜８重量％であり、かつホエイタンパク質に対するカゼインタンパク質のタンパク質量比（カゼインタンパク質／ホエイタンパク質）が２〜２０である疲労改善用食品組成物、
［１２］乳タンパク質混合物が総タンパク質量で一日あたり０．０６ｇ／ｋｇ体重以上となるように摂取される、［１１］に記載の疲労改善用食品組成物、
［１３］１〜８週間継続して摂取されることを特徴とする、［１１］または［１２］に記載の疲労改善用食品組成物、
［１４］一食あたりの単位包装形態からなり、該単位包装形態中に、乳タンパク質混合物を一食摂取量として総タンパク質量で３ｇ以上含む、［１１］〜［１３］のいずれか１に記載の疲労改善用食品組成物、
［１５］運動する対象により摂取される、［１１］〜［１４］のいずれか１に記載の疲労改善用食品組成物、
［１６］カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を含む乳性液状組成物の疲労改善における使用であって、乳性液状組成物において、乳タンパク質混合物の濃度が４〜８重量％であり、かつホエイタンパク質に対するカゼインタンパク質のタンパク質量比（カゼインタンパク質／ホエイタンパク質）が２〜２０である使用、
［１７］カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を含む乳性液状組成物の、疲労改善剤の製造における使用であって、乳性液状組成物において、乳タンパク質混合物の濃度が４〜８重量％であり、かつホエイタンパク質に対するカゼインタンパク質のタンパク質量比（カゼインタンパク質／ホエイタンパク質）が２〜２０である使用。That is, the present invention is as follows.
[1] A fatigue improving agent comprising a milky liquid composition containing a milk protein mixture containing casein protein and whey protein as an active ingredient, wherein the concentration of the milk protein mixture in the milky liquid composition is 4 to 8 A fatigue ameliorating agent, the weight percentage of which is a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20,
[2] The fatigue-improving agent according to [1], wherein the milk protein mixture is ingested so that the total protein amount is 0.06 g / kg body weight or more per day,
[3] The fatigue ameliorating agent according to [1] or [2], characterized in that it is taken continuously for 1 to 8 weeks,
[4] The unit packaging form according to any one of [1] to [3], comprising a unit packaging form per serving, wherein the unit packaging form includes a milk protein mixture in a total protein amount of 3 g or more as a meal intake. Fatigue relieving agents,
[5] The fatigue improving agent according to any one of [1] to [4], which is ingested by a subject to exercise.
[6] including a step of ingesting a milky liquid composition containing a milk protein mixture containing casein protein and whey protein, wherein the milk protein mixture has a concentration of 4 to 8% by weight in the milky liquid composition. A method for improving fatigue (excluding medical practice for humans), wherein the protein amount ratio of casein protein to whey protein (casein protein / whey protein) is 2 to 20,
[7] The method for improving fatigue according to [6], wherein the milk protein mixture is ingested so that the total protein amount is 0.06 g / kg body weight or more per day,
[8] The method for improving fatigue according to [6] or [7], wherein the method is continuously ingested for 1 to 8 weeks,
[9] The dairy liquid composition comprises a unit packaging form per meal, and the unit packaging form contains 3 g or more of the milk protein mixture as a meal intake in a total protein amount [6] to [8] The fatigue improving method according to any one of
[10] The fatigue improvement method according to any one of [6] to [9], which is ingested by a subject to exercise.
[11] A food composition for improving fatigue comprising a milky liquid composition containing a milk protein mixture containing casein protein and whey protein as an active ingredient, wherein the milk protein mixture in the milky liquid composition A fatigue-reducing food composition having a concentration of 4 to 8% by weight and a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20,
[12] The food composition for improving fatigue according to [11], wherein the milk protein mixture is ingested so that the total protein amount is 0.06 g / kg body weight or more per day,
[13] The food composition for improving fatigue according to [11] or [12], wherein the food composition is continuously ingested for 1 to 8 weeks,
[14] The unit packaging form according to any one of [11] to [13], comprising a unit packaging form per serving, wherein the unit packaging form includes a milk protein mixture in a total protein amount of 3 g or more as a meal intake. A food composition for improving fatigue,
[15] The food composition for fatigue improvement according to any one of [11] to [14], which is ingested by a subject to exercise.
[16] Use of a dairy liquid composition containing a milk protein mixture containing casein protein and whey protein in improving fatigue, wherein the concentration of the milk protein mixture is 4 to 8% by weight in the dairy liquid composition And the protein amount ratio of casein protein to whey protein (casein protein / whey protein) is 2 to 20,
[17] Use of a milky liquid composition containing a milk protein mixture containing casein protein and whey protein in the manufacture of a fatigue ameliorating agent, wherein the concentration of the milk protein mixture is 4 to 8 in the milky liquid composition. Use in which the protein amount ratio of casein protein to whey protein (casein protein / whey protein) is 2 to 20% by weight.
本発明では、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を含む乳性液状組成物を有効成分として含んでなる疲労改善剤であって、乳性液状組成物における乳タンパク質混合物の濃度が４〜８重量％であり、かつホエイタンパク質に対するカゼインタンパク質のタンパク質量比（カゼインタンパク質／ホエイタンパク質）が２〜２０である疲労改善剤を提供することができる。 In this invention, it is a fatigue improving agent which contains the milky liquid composition containing the milk protein mixture containing casein protein and whey protein as an active ingredient, Comprising: The density | concentration of the milk protein mixture in a milky liquid composition is 4 ~ It is possible to provide a fatigue ameliorating agent that is 8% by weight and has a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20.
以下では、本発明を詳細に説明するが、本発明は、個々の形態には限定されない。 Hereinafter, the present invention will be described in detail, but the present invention is not limited to individual forms.
本発明は、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を含む乳性液状組成物を有効成分として含んでなる疲労改善剤であって、乳性液状組成物における乳タンパク質混合物の濃度が４〜８重量％であり、かつホエイタンパク質に対するカゼインタンパク質のタンパク質量比（カゼインタンパク質／ホエイタンパク質）が２〜２０である疲労改善剤である。 The present invention is a fatigue ameliorating agent comprising as an active ingredient a milky liquid composition comprising a milk protein mixture containing casein protein and whey protein, wherein the milk protein mixture has a concentration of 4 to 4 in the milky liquid composition. The fatigue-improving agent is 8% by weight and has a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20.
「有効成分」とは疲労改善効果を奏する上で必要とされる成分のことを意味する。一つの形態として、「有効成分」とは、疲労改善を必要とする対象のための疲労改善効果を奏する上での必要とされる成分のことを意味する。 “Active ingredient” means an ingredient required for exerting a fatigue improving effect. As one form, an “active ingredient” means a component that is required for exerting a fatigue improvement effect for a subject that requires fatigue improvement.
「疲労改善を必要とする対象」とは、蓄積された疲労感を解消するために、疲労改善を促進する必要がある対象を意味し、例えば、健康増進や運動能力向上を目的として、筋肉合成の促進、筋肉喪失の予防、および筋肉量の回復促進のために、運動する対象、有酸素運動を継続して持久力や免疫力の向上を促進するために、運動する対象を意味する。 “Subjects requiring improvement in fatigue” means subjects who need to promote improvement of fatigue in order to eliminate the accumulated feeling of fatigue. For example, for the purpose of improving health and improving exercise capacity, muscle synthesis It means a subject who exercises for the purpose of promoting muscle loss, preventing muscle loss, and promoting recovery of muscle mass, and a subject who exercises in order to continue aerobic exercise and promote improvement of endurance and immunity.
本発明の疲労改善剤を摂取する対象は、運動する対象であることができ、例えば、スポーツ選手、スポーツ愛好者（アスリート）、生活習慣病の改善のために運動を必要とする者、高齢者などの健康増進のために運動を必要とする者、筋肉損傷疾患（例えば、サルコペニア）を患い、運動により筋肉合成の促進を必要とする患者、病後に肺活量や免疫力を高めるために適度な運動を必要とする患者、または運動と同程度に労働もしくは作業を行う者などが挙げられる。また、この対象には、ヒト以外の動物（馬、牛などの家畜、犬、猫などの愛玩動物、動物園などで飼育されている鑑賞動物など）であってもよい。 The subject ingesting the fatigue relieving agent of the present invention can be a subject to exercise, for example, an athlete, a sports enthusiast (athlete), a person who needs exercise to improve lifestyle-related diseases, an elderly person Those who need exercise to improve their health, such as those who suffer from muscle damage diseases (eg sarcopenia) and who need to promote muscle synthesis through exercise, moderate exercise to increase lung capacity and immunity after illness Patients who need health care, or those who work or work as much as exercise. Further, the target may be an animal other than a human (domestic animals such as horses and cows, pets such as dogs and cats, appreciation animals kept in zoos, etc.).
本発明の疲労改善剤を摂取する対象に摂取させる（投与する）時期は、運動前であっても運動後であっても運動中であってもよい。ここで、この摂取させる時期は、好ましくは、運動後である。ここでいう、運動は、その性質や強弱において特に制限はないが、例えば、運動愛好家による運動競技、学校の運動部での運動競技、家事労働、農作業、工事現場などでの現場労働、工場などでの立ち仕事、に相当する運動である。 The time to ingest (administer) the fatigue ameliorating agent of the present invention may be before exercise, after exercise, or during exercise. Here, the time of intake is preferably after exercise. There is no particular restriction on the nature and strength of the exercise here. For example, athletics by athletic enthusiasts, athletics at the sports department of the school, domestic labor, farm work, field work at construction sites, factories, etc. It is an exercise equivalent to standing work.
本発明の疲労改善とは、体感的に疲労が改善された状態をいう。例えば、本発明の疲労改善剤を摂取しない場合に比べての体感的な疲労改善がなされた状態をいう。また、例えば、後述する継続摂取した場合において、習慣的な運動をした場合における、継続摂取の初期で体感した疲労感に比べて、継続摂取中の疲労感が改善された状態をもいう。これらの絶対的および／または相対的な体感から来る疲労感の改善が見られた場合に、疲労改善作用として有意であると判断できる。本発明における疲労とは、運動あるいは運動に相当する労働および作業等により蓄積される疲労をいう。
このような疲労改善の指標は、例えば、そのときの体感をビジュアルアナログスケール（ＶＡＳ）によるスコアで表すことができる。例えば、「何もできないほど疲れ切った最悪の感覚」と感じられる場合を０、「疲れを全く感じない最良の感覚」と感じられる場合を１００として、被験者のＶＡＳによるスコアを集計して指標とすることができる。このＶＡＳスコアの他に、疲労改善を示唆する体内物質の含有量を指標にしてもよい。The fatigue improvement of the present invention refers to a state in which fatigue has been improved sensibly. For example, it refers to a state in which physical fatigue has been improved as compared to the case where the agent for improving fatigue according to the present invention is not taken. In addition, for example, in the case of continuous ingestion described later, it also refers to a state in which the feeling of fatigue during continuous ingestion is improved as compared to the feeling of fatigue experienced at the initial stage of continuous ingestion when performing habitual exercise. When the improvement of the fatigue feeling which comes from these absolute and / or relative physical feeling is seen, it can be judged that it is significant as a fatigue improvement effect. The fatigue in the present invention refers to fatigue accumulated by exercise or labor or work corresponding to exercise.
For example, such an index for improving fatigue can be expressed by a score based on a visual analog scale (VAS). For example, assuming that “the worst sensation exhausted so that nothing can be done” is 0, and “100 is the best sensation that does not feel fatigue at all” is 100, the subject's score by VAS is aggregated as an index. can do. In addition to this VAS score, the content of a body substance that suggests improvement in fatigue may be used as an index.
「タンパク質量」とは、乳タンパク質、ホエイタンパク質またはカゼインタンパク質の各種のタンパク質に含まれるアミノ酸の高分子としてのタンパク質の量を意味する。「タンパク質量比」とは、乳タンパク質、ホエイタンパク質またはカゼインタンパク質の各種のタンパク質に含まれるアミノ酸の高分子としてのタンパク質の量の比率を意味する。ここで、タンパク質量は、例えば、食品成分表などの公知の情報に基づいて算出してもよく、また、ケルダール法やローリー法などの慣用の方法によって測定して算出してもよい。実際に、ケルダール法の場合には、各種のタンパク質に含まれる窒素を測定し、その値に、窒素−タンパク質換算係数（通常 ６．２５）を乗じて算出することができる。 “Protein amount” means the amount of protein as a polymer of amino acids contained in various proteins such as milk protein, whey protein or casein protein. “Protein amount ratio” means the ratio of the amount of protein as a polymer of amino acids contained in various proteins such as milk protein, whey protein, or casein protein. Here, the amount of protein may be calculated based on known information such as a food composition table, or may be calculated by measuring by a conventional method such as Kjeldahl method or Raleigh method. Actually, in the case of the Kjeldahl method, it can be calculated by measuring nitrogen contained in various proteins and multiplying the value by a nitrogen-protein conversion factor (usually 6.25).
本発明に用いられる乳タンパク質混合物は、ホエイタンパク質とカゼインタンパク質とを特定のタンパク質量比で含んでいれば特に限定されず、別々に分離や精製されたホエイタンパク質とカゼインタンパク質とを特定のタンパク質量比になるように混合して調製してもよいし、あるいは、別々に分離や精製されていないホエイタンパク質とカゼインタンパク質とを既に特定のタンパク質量比で含んでいる原料（素材）や飲食品などを混合して調製してもよい。このとき、本発明に用いられる乳タンパク質混合物では、ホエイタンパク質やカゼインタンパク質の分離工程や精製工程を必要とせず、それらの製造費が安価である点で、ホエイタンパク質とカゼインタンパク質とを既に特定のタンパク質量比で含んでいる原料や飲食品などを主要な成分とし、必要に応じて、別々に精製されたホエイタンパク質やカゼインタンパク質とを特定のタンパク質量比になるように混合して調製することが好ましい。 The milk protein mixture used in the present invention is not particularly limited as long as it contains whey protein and casein protein in a specific protein amount ratio, and the whey protein and casein protein separated and purified separately have a specific protein amount. It may be prepared by mixing so as to achieve a ratio, or a raw material (material) or food / drink that already contains whey protein and casein protein that are not separately separated or purified in a specific protein ratio May be prepared by mixing. At this time, the milk protein mixture used in the present invention does not require a separation step or purification step of whey protein or casein protein, and the production cost thereof is low, so that whey protein and casein protein are already specified. Prepared by mixing the raw materials and foods and drinks that are contained in the protein content ratio as the main components, and mixing the whey protein and casein protein purified separately as needed to achieve a specific protein content ratio. Is preferred.
カゼインタンパク質と別々に分離や精製されたホエイタンパク質には、例えば、ホエイの原液（甘性ホエイ、酸ホエイなど）、その濃縮物、その乾燥物（ホエイ粉など）、その凍結物、その加水分解物など、および、これらの還元溶液などを用いることができる。さらに、脱塩ホエイ、ホエイタンパク質濃縮物（ＷＰＣ）、ホエイタンパク質精製物（ＷＰＩ）、α−ラクトアルブミン（α−Ｌａ）、β−ラクトグロブリン（β−Ｌｇ）、免疫グロブリン、ラクトフェリンなど、および、これらの還元溶液を用いることができる。そして、ホエイタンパク質と別々に分離や精製されたカゼインタンパク質には、例えば、カゼインの分離物（フレッシュチーズなどのナチュラルチーズ、ナトリウムカゼイネート、カルシウムカゼイネートなど）、その濃縮物、その乾燥物、その凍結物、その加水分解物など、および、これらの還元溶液などを用いることができる。さらに、α−カゼイン、β−カゼイン、ｋ−カゼインなどの精製物、および、これらの還元溶液を用いることができる。また、ホエイタンパク質とカゼインタンパク質とを既に特定のタンパク質量比で含んでいる原料や飲食品には、例えば、生乳、殺菌乳（牛乳など）、脱脂乳、成分調整牛乳、加工乳、乳製品（濃縮乳、粉乳、練乳、発酵乳（ヨーグルトなど）、乳酸菌飲料、プロセスチーズ類、アイスクリーム類、クリーム類）、乳タンパク質濃縮物（ＭＰＣ）、その濃縮物、その乾燥物、その凍結物、その加水分解物など、および、これらの還元溶液などを用いることができる。このとき、これらには、市販品を入手して用いてもよいし、自ら調製して用いてもよい。中でも、本発明の乳性液状組成物を、高濃度のカゼインタンパク質を含有する乳性液状組成物とする場合には、カゼインタンパク質を豊富に含有する乳原料である、乳タンパク質濃縮物（ＭＰＣ）を使用することが好ましい。この乳タンパク質濃縮物において、カゼインタンパク質とホエイタンパク質とのタンパク質量比（カゼインタンパク質／ホエイタンパク質）は、４である。 Examples of whey protein separated and purified separately from casein protein include whey stock solutions (sweet whey, acid whey, etc.), concentrates, dried products (whey powder, etc.), frozen products, hydrolyzed products, etc. And reducing solutions thereof. Furthermore, desalted whey, whey protein concentrate (WPC), whey protein purified product (WPI), α-lactalbumin (α-La), β-lactoglobulin (β-Lg), immunoglobulin, lactoferrin and the like, and These reducing solutions can be used. Casein protein separated and purified separately from whey protein includes, for example, casein isolate (natural cheese such as fresh cheese, sodium caseinate, calcium caseinate), its concentrate, its dried product, its A frozen material, a hydrolyzate thereof, a reducing solution thereof, and the like can be used. Furthermore, purified products such as α-casein, β-casein, k-casein, and reducing solutions thereof can be used. In addition, raw materials and foods and beverages that already contain whey protein and casein protein in a specific protein ratio include, for example, raw milk, pasteurized milk (such as milk), skim milk, component-adjusted milk, processed milk, and dairy products ( Concentrated milk, powdered milk, condensed milk, fermented milk (yogurt, etc.), lactic acid bacteria beverages, processed cheeses, ice creams, creams), milk protein concentrate (MPC), its concentrate, its dried product, its frozen product, its Hydrolysates and the like, and reducing solutions thereof can be used. At this time, you may obtain and use a commercial item for these, and may prepare and use it for themselves. In particular, when the dairy liquid composition of the present invention is a dairy liquid composition containing a high concentration of casein protein, a milk protein concentrate (MPC) which is a milk raw material rich in casein protein Is preferably used. In this milk protein concentrate, the protein amount ratio between casein protein and whey protein (casein protein / whey protein) is 4.
本発明で用いられる乳タンパク質混合物は、特定のタンパク質量比のホエイタンパク質とカゼインタンパク質とから構成され、具体的には、カゼインタンパク質とホエイタンパク質とのタンパク質量比（カゼインタンパク質／ホエイタンパク質）が２〜２０であり、好ましくは２〜１０であり、より好ましくは２〜６であり、さらに好ましくは２〜４であり、特に好ましくは２〜３．５である。なお、本発明で用いられる乳タンパク質混合物では、カゼインタンパク質とホエイタンパク質とのタンパク質量比（カゼインタンパク質／ホエイタンパク質）が意図的に調整（設計）されている点で、従来技術とは大きく異なっている。 The milk protein mixture used in the present invention is composed of whey protein and casein protein having a specific protein amount ratio, and specifically, the protein amount ratio (casein protein / whey protein) of casein protein to whey protein is 2. It is -20, Preferably it is 2-10, More preferably, it is 2-6, More preferably, it is 2-4, Most preferably, it is 2-3.5. In the milk protein mixture used in the present invention, the protein ratio (casein protein / whey protein) between casein protein and whey protein is intentionally adjusted (designed), which is greatly different from the conventional technology. Yes.
本発明の乳性液状組成物に含まれる乳タンパク質混合物の濃度は、本発明の疲労改善効果が奏される範囲であればよい。具体的には、本発明の乳性液状組成物に含まれる乳タンパク質混合物の濃度は、例えば、４〜８重量％、４〜７．５重量％、４〜７重量％、４〜６．５重量％、４〜６重量％、４．５〜５．５重量％、４．７〜５．３重量％、４．８〜５．２重量％である。ここで、本発明の乳性液状組成物に含まれる乳タンパク質混合物の濃度が４重量％以上であれば、本発明の疲労改善効果が奏され好ましい。また、本発明の乳性液状組成物に含まれる乳タンパク質混合物の濃度が８重量％以下であれば、本発明の疲労改善剤を摂取することに負担がないため、好ましい。 The density | concentration of the milk protein mixture contained in the milky liquid composition of this invention should just be a range with which the fatigue improvement effect of this invention is show | played. Specifically, the concentration of the milk protein mixture contained in the milky liquid composition of the present invention is, for example, 4 to 8% by weight, 4 to 7.5% by weight, 4 to 7% by weight, or 4 to 6.5. % By weight, 4-6% by weight, 4.5-5.5% by weight, 4.7-5.3% by weight, and 4.8-5.2% by weight. Here, if the density | concentration of the milk protein mixture contained in the milky liquid composition of this invention is 4 weight% or more, the fatigue improvement effect of this invention will be show | played and it is preferable. Moreover, if the density | concentration of the milk protein mixture contained in the milky liquid composition of this invention is 8 weight% or less, since there is no burden in ingesting the fatigue improving agent of this invention, it is preferable.
本発明の乳性液状組成物は、乳タンパク質混合物の濃度が４〜８重量％であれば、公知の乳性液状組成物（例えば、牛乳、乳飲料）の製造方法を応用して製造することができる。すなわち、例えば、原料を溶解し、均質化して、加熱殺菌をすることにより製造することができる。 If the density | concentration of a milk protein mixture is 4 to 8 weight%, the milky liquid composition of this invention applies and manufactures the manufacturing method of a well-known milky liquid composition (for example, milk, milk drink). Can do. That is, for example, it can be produced by dissolving, homogenizing, and sterilizing by heating.
本発明の乳性液状組成物は、その保存性を高めるために、加熱殺菌をすることができる。本発明の乳性液状組成物の製造方法における、本発明の乳性液状組成物の加熱殺菌の方法は、公知の牛乳及び／又は飲料の殺菌方法及び殺菌条件を設定することができる。殺菌方法は、例えば、プレート式加熱殺菌、チューブ式加熱殺菌、バッチ式加熱殺菌、通電加熱殺菌、マイクロウエーブ波による加熱殺菌、レトルト加熱などの間接加熱殺菌、スチームインジェクション、スチームインフュージョンなどの直接加熱殺菌である。殺菌条件は、牛乳と同じく、例えば、６０〜６５℃で２０〜３０分間保持、８０〜１００℃で１５秒〜１０分間保持、１１０℃〜１５０℃で２〜１５秒間保持であり、これと同等の殺菌条件であれば、適宜変更することができる。 The dairy liquid composition of the present invention can be sterilized by heating in order to increase its storage stability. In the method for producing a milky liquid composition of the present invention, the heat sterilization method of the milky liquid composition of the present invention can be set to known milk and / or beverage sterilization methods and sterilization conditions. Sterilization methods include, for example, plate-type heat sterilization, tube-type heat sterilization, batch-type heat sterilization, current heat sterilization, microwave wave heat sterilization, indirect heat sterilization such as retort heating, direct injection such as steam injection, steam infusion, etc. Sterilization. The sterilization conditions are the same as milk, for example, holding at 60 to 65 ° C. for 20 to 30 minutes, holding at 80 to 100 ° C. for 15 seconds to 10 minutes, holding at 110 ° C. to 150 ° C. for 2 to 15 seconds, and equivalent to this If it is sterilization conditions, it can change suitably.
本発明の乳性液状組成物の製造方法において、本発明の乳性液状組成物の保存性を高めるために、非加熱殺菌をすることができる。本発明の乳性液状組成物の製造方法における、本発明の乳性液状組成物の非加熱殺菌の方法は、公知の殺菌方法及び殺菌条件を設定することができる。非加熱殺菌の殺菌方法は、例えば、光照射殺菌、放射線照射殺菌、高電圧パルス殺菌などである。非加熱殺菌の殺菌条件は、牛乳の加熱殺菌と同じ殺菌効果、例えば、６０〜６５℃で２０〜３０分間保持、８０〜１００℃で１５秒〜１０分間保持、１１０℃〜１５０℃で２〜１５秒間保持であり、これと同等の殺菌効果があれば、非加熱殺菌の殺菌条件を適宜変更することができる。 In the method for producing a milky liquid composition of the present invention, non-heat sterilization can be performed in order to enhance the storage stability of the milky liquid composition of the present invention. In the method for producing a dairy liquid composition of the present invention, the non-heat sterilization method of the dairy liquid composition of the present invention can be set with known sterilization methods and sterilization conditions. Non-heat sterilization methods include, for example, light irradiation sterilization, radiation irradiation sterilization, and high voltage pulse sterilization. The sterilization conditions for non-heat sterilization are the same sterilization effects as the heat sterilization of milk, for example, hold at 60 to 65 ° C. for 20 to 30 minutes, hold at 80 to 100 ° C. for 15 seconds to 10 minutes, and at 110 to 150 ° C. If the sterilization effect is equivalent to this for 15 seconds, the sterilization conditions for non-heat sterilization can be appropriately changed.
本発明の乳性液状組成物の製造方法において、殺菌された本発明の乳性液状組成物を冷却することができる。最終的に冷却された乳性液状組成物の温度は、例えば、０〜３０℃、０〜２５℃、０〜２０℃、０〜１５℃、０〜１２℃、０〜１０℃である。 In the method for producing a milky liquid composition of the present invention, the sterilized milky liquid composition of the present invention can be cooled. The temperature of the finally cooled dairy liquid composition is, for example, 0-30 ° C, 0-25 ° C, 0-20 ° C, 0-15 ° C, 0-12 ° C, 0-10 ° C.
本発明の乳性液状組成物は、本発明の特徴である、疲労改善効果が得られれば、その他の食品原料及び／又は食品添加物原料を添加することができる。例えば、本発明の乳性液状組成物の嗜好性の付与を目的に、甘味料（砂糖類、液糖類、果糖、麦芽糖、三温糖など）、糖アルコール（エリスリトールなど）、高感度甘味料（ステビア、アスパルテーム、スクラロース、アセスルファムカリウム）、香料、果汁、野菜汁などを添加することができる。また、本発明の乳性液状組成物の機能性の付与を目的に、ミネラル類（カルシウム、鉄、マンガン、マグネシウム、亜鉛など）、ビタミン類、機能性素材、プロバイオティクス乳酸菌などを添加して、本発明の疲労改善剤とすることができる。 The dairy liquid composition of the present invention can be added with other food raw materials and / or food additive raw materials as long as the fatigue improving effect that is a feature of the present invention is obtained. For example, for the purpose of imparting the palatability of the milky liquid composition of the present invention, sweeteners (sugars, liquid sugars, fructose, maltose, trisaccharide, etc.), sugar alcohols (erythritol, etc.), high-sensitivity sweeteners ( Stevia, aspartame, sucralose, acesulfame potassium), fragrance, fruit juice, vegetable juice and the like can be added. For the purpose of imparting the functionality of the milky liquid composition of the present invention, minerals (calcium, iron, manganese, magnesium, zinc, etc.), vitamins, functional materials, probiotic lactic acid bacteria, etc. are added. The fatigue improving agent of the present invention can be used.
本発明の疲労改善剤は、市場での提供を目的として、容器詰飲料、容器入り飲料の形態にすることができる。容器は、紙容器（ゲーブルトップ型容器、ブリック型容器など）、ソフトバック、ペットボトル、缶、ビンなど、公知のものを使用することができる。容器の容量は、特に制限はなく、例えば、１０〜５０００ｍｌ、２０〜４０００ｍｌ、３０〜３０００ｍｌ、４０〜２０００ｍｌ、５０〜１５００ｍｌ、６０〜１４００ｍｌ、７０〜１３００ｍｌ、８０〜１２００ｍｌ、９０〜１１００ｍｌである。中でも、ファミリーサイズ（複数飲用）の場合には、例えば、３００〜５０００ｍｌ、３００〜４０００ｍｌ、３００〜３０００ｍｌ、３００〜２０００ｍｌ、３００〜１５００ｍｌ、３００〜１４００ｍｌ、３００〜１３００ｍｌ、３００〜１２００ｍｌ、３００〜１１００ｍｌであり、パーソナルサイズ（個別飲用）の場合、１０〜５００ｍｌ、２０〜５００ｍｌ、３０〜５００ｍｌ、４０〜５００ｍｌ、５０〜５００ｍｌ、６０〜５００ｍｌ、７０〜５００ｍｌ、８０〜５００ｍｌ、９０〜５００ｍｌである。 The fatigue reducing agent of the present invention can be in the form of a container-packed beverage or a container-containing beverage for the purpose of providing in the market. A well-known thing, such as a paper container (a gable top type container, a brick type container, etc.), a soft bag, a plastic bottle, a can, a bottle, can be used for a container. There is no restriction | limiting in particular in the capacity | capacitance of a container, For example, they are 10-5000 ml, 20-4000 ml, 30-3000 ml, 40-2000 ml, 50-1500 ml, 60-1400 ml, 70-1300 ml, 80-1200 ml, 90-1100 ml. Above all, in the case of family size (multiple drinks), for example, 300-5000 ml, 300-4000 ml, 300-3000 ml, 300-2000 ml, 300-1500 ml, 300-1400 ml, 300-1300 ml, 300-1200 ml, 300-1100 ml In the case of personal size (individual drinking), it is 10-500 ml, 20-500 ml, 30-500 ml, 40-500 ml, 50-500 ml, 60-500 ml, 70-500 ml, 80-500 ml, 90-500 ml.
本発明の疲労改善剤は、疲労改善効果を高めることができれば、市場への提供形態に制限はない。例えば、本発明の疲労改善剤では、１０℃以下のチルド流通、常温流通が可能である。また、本発明の疲労改善剤は、耐熱効果もある。従って、本発明の疲労改善剤を配合（添加、混合）した組成物では、本発明の疲労改善剤が耐熱効果を奏することから、好ましくは、液状の製品形態として提供することができるととともに、ホットベンダーなどを用いた加温販売用の製品形態として提供することができる。 If the fatigue improvement agent of this invention can heighten the fatigue improvement effect, there will be no restriction | limiting in the form provided to a market. For example, in the fatigue improving agent of the present invention, chilled distribution at 10 ° C. or lower and normal temperature distribution are possible. The fatigue improving agent of the present invention also has a heat resistance effect. Therefore, in the composition in which the fatigue improver of the present invention is blended (added, mixed), since the fatigue improver of the present invention has a heat-resistant effect, preferably, it can be provided as a liquid product form, It can be provided as a product form for warm sales using a hot vendor or the like.
本発明の一つの実施態様によれば、例えば、本発明の疲労改善剤では、前記乳タンパク質混合物が総タンパク質量で一食あたり０．０６ｇ以上／ｋｇ体重となるように摂取（投与）され、例えば、０．０６〜０．７ｇ／ｋｇ体重、０．０６〜０．６ｇ／ｋｇ体重、０．０６〜０．５ｇ／ｋｇ体重、０．０８〜０．４ｇ／ｋｇ体重、０．１〜０．４ｇ／ｋｇ体重となるように摂取（投与）される。ここで、対象の代表的な体重は、約６０ｋｇと見積もっている。ここで、本発明の疲労改善剤における、前記乳タンパク質混合物が総タンパク質量で一食あたり０．０６ｇ以上／ｋｇ体重であれば、本発明の疲労改善効果が奏され好ましい。 According to one embodiment of the present invention, for example, in the fatigue ameliorating agent of the present invention, the milk protein mixture is ingested (administered) so that the total protein amount is 0.06 g / kg body weight per meal, 0.06-0.7 g / kg body weight, 0.06-0.6 g / kg body weight, 0.06-0.5 g / kg body weight, 0.08-0.4 g / kg body weight, 0.1-0 Ingested (administered) to 4 g / kg body weight. Here, the typical weight of the subject is estimated to be about 60 kg. Here, in the fatigue improving agent of the present invention, if the milk protein mixture is 0.06 g or more / kg body weight per serving in terms of total protein, the fatigue improving effect of the present invention is exhibited and preferable.
「一食」とは、疲労改善を必要とする状態の一回ごとを意味し、例えば、本発明の疲労改善剤では、一食で一息に（一度に）摂取せず、数度に分けて摂取してもよい。本発明の疲労改善剤を、疲労改善を必要とする対象に摂取させる（投与する）時期は、数度に分けて摂取する場合には、任意にその時刻を選択できる。例えば、本発明の疲労改善剤を１日に２回摂取する場合には、例えば、運動前後、朝晩、などである。 The term “one meal” means each time a state requiring fatigue improvement. For example, in the fatigue-improving agent of the present invention, a single meal is not taken at a time (at a time) and divided into several degrees. May be taken. The time when the fatigue-improving agent of the present invention is ingested (administered) by a subject in need of fatigue improvement can be arbitrarily selected when ingested in several degrees. For example, when the fatigue ameliorating agent of the present invention is taken twice a day, for example, before and after exercise, morning and evening.
本発明の疲労改善剤を、疲労改善を必要とする対象に摂取させる（投与する）方法は、経口摂取（経口投与）、経腸投与、胃ろうなどから、その対象および用途により、適宜選択することができるが、好ましくは経口摂取である。 The method for ingesting (administering) the fatigue ameliorating agent of the present invention to a subject in need of fatigue is appropriately selected according to the subject and application from oral ingestion (oral administration), enteral administration, gastric fistula and the like. Preferably, it is taken orally.
本発明の別の実施態様によれば、例えば、本発明の疲労改善剤は、一食あたりの単位包装形態からなり、該単位中に、前記乳タンパク質混合物を、一食摂取量として総タンパク質量で３ｇ以上に調整したものが望ましく、例えば、３〜４０ｇ、３〜２０ｇ、４〜２０ｇ、４〜１５ｇ、５〜１５ｇとなるように調製してなる。ここで、「一食あたりの単位包装形態」からなるとは、一食あたりの摂取量があらかじめ定められた形態のものであり、例えば、特定量を経口摂取し得る飲食品として、一般食品のみならず、飲料（ドリンク剤など）、健康補助食品、保健機能食品、サプリメントなどの形態を意味する。「一食あたりの単位包装形態」では、例えば、液状の飲料、ゲル状・糊状・ペースト状のゼリー、粉末状・顆粒状・カプセル状・ブロック状の固体状の食品などの場合には、金属缶、ガラスビン（ボトルなど）、プラスチック容器（ペットボトルなど）、パック、パウチ、フィルム容器、紙箱などの包装容器で特定量（用量）を規定できる形態、あるいは、一食あたりの摂取量（用法、用量）を包装容器やホームページなどに表示することで特定量を規定できる形態が挙げられる。 According to another embodiment of the present invention, for example, the fatigue ameliorating agent of the present invention comprises a unit package form per serving, and the milk protein mixture is contained in the unit as a total amount of protein as a single meal intake. What adjusted to 3 g or more is desirable, for example, it is prepared so that it may become 3-40 g, 3-20 g, 4-20 g, 4-15 g, 5-15 g. Here, `` consisting of a unit packaging form per meal '' is a form in which the intake amount per meal is determined in advance, for example, as a food and drink that can be taken orally in a specific amount, not only general foods, It means forms such as beverages (drinks, etc.), health supplements, health functional foods, and supplements. In "unit packaging form per meal", for example, in the case of liquid beverages, gel-like, paste-like, paste-like jelly, powder-like, granule-like, capsule-like, block-like solid foods, etc. A specific amount (dose) can be defined in packaging containers such as cans, glass bottles (such as bottles), plastic containers (such as plastic bottles), packs, pouches, film containers, paper boxes, etc., or intake per serving (usage, dose) ) Is displayed on a packaging container, a homepage, etc., and the form which can prescribe | regulate a specific quantity is mentioned.
本発明の一つの実施態様によれば、例えば、本発明の疲労改善剤では、疲労改善剤を含んでなる組成物を提供することができる。すなわち、本発明の疲労改善剤では、そのまま単独で使用することができるが、疲労改善機能が発揮される限りにおいて、飲食品や医薬品などの種々の経口摂取用（経口投与用）の組成物に対して、原料（素材）や添加剤などとして含ませることもでき、即効的な疲労改善効果を有する組成物を得ることができる。よって、本発明の一つの実施態様によれば、本発明の疲労改善剤を含んでなる組成物が提供される。 According to one embodiment of the present invention, for example, the fatigue ameliorating agent of the present invention can provide a composition comprising the fatigue ameliorating agent. That is, the fatigue ameliorating agent of the present invention can be used alone as it is, but as long as the fatigue ameliorating function is exhibited, it can be used for various oral intake (oral administration) compositions such as foods and drinks and pharmaceuticals. On the other hand, it can also be included as a raw material (raw material), an additive, etc., and a composition having an immediate fatigue improvement effect can be obtained. Therefore, according to one embodiment of the present invention, a composition comprising the fatigue improving agent of the present invention is provided.
本発明の別の実施形態によれば、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を含む乳性液状組成物を有効成分として含んでなる疲労改善用食品組成物であって、前記乳性液状組成物における前記乳タンパク質混合物の濃度が４〜８重量％であり、かつホエイタンパク質に対するカゼインタンパク質のタンパク質量比（カゼインタンパク質／ホエイタンパク質）が２〜２０である疲労改善用食品組成物が提供される。ここで、「食品組成物」には、一般食品および飲料だけでなく、健康補助食品、保健機能食品、特定保健用食品、サプリメント、食品添加物および飼料などが含まれる。本発明の疲労改善用食品組成物は、例えば、疲労改善のために用いる旨の表示を付した食品であることができる。本発明の疲労改善用食品組成物は、乳タンパク質混合物が総タンパク質量で一日あたり０．０６ｇ／ｋｇ体重以上摂取されるように構成された形態であってもよい。また、本発明の疲労改善用食品組成物は、一食あたりの単位包装形態からなり、該単位包装形態中に、乳タンパク質混合物が一食摂取量として総タンパク質量で３ｇ以上含まれてもよい。本発明の疲労改善用食品組成物は、本発明の疲労改善剤について本願明細書に記載された内容に従って実施することができる。 According to another embodiment of the present invention, there is provided a food composition for improving fatigue comprising as an active ingredient a milky liquid composition comprising a milk protein mixture containing casein protein and whey protein, wherein said milky liquid Provided is a food composition for improving fatigue, wherein the concentration of the milk protein mixture in the composition is 4 to 8% by weight and the ratio of casein protein to whey protein (casein protein / whey protein) is 2 to 20 The Here, the “food composition” includes not only general foods and drinks but also health supplements, health functional foods, foods for specified health use, supplements, food additives and feeds. The food composition for improving fatigue according to the present invention can be, for example, a food with an indication that it is used for improving fatigue. The food composition for improving fatigue according to the present invention may be configured such that the milk protein mixture is ingested in a total protein amount of 0.06 g / kg body weight or more per day. Moreover, the food composition for improving fatigue according to the present invention comprises a unit packaging form per serving, and the milk protein mixture may be contained in the unit packaging form in an amount of 3 g or more in terms of the total protein intake. The food composition for improving fatigue according to the present invention can be carried out according to the contents described in the present specification for the fatigue improving agent of the present invention.
本発明のさらに別の実施態様によれば、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を含む乳性液状組成物を対象に摂取させる工程を含み、乳性液状組成物において、乳タンパク質混合物の濃度が４〜８重量％であり、かつホエイタンパク質に対するカゼインタンパク質のタンパク質量比（カゼインタンパク質／ホエイタンパク質）が２〜２０である疲労改善方法（ヒトに対する医療行為を除く）が提供される。ここで、「ヒトに対する医療行為」とは、医師等の処方を必要として、ヒトに対して医薬品を摂取させる（投与する）行為などを意味する。本発明の疲労改善方法は、本発明の疲労改善剤について、本願明細書に記載された内容に従って実施することができる。 According to still another embodiment of the present invention, the method comprises the step of ingesting a milky liquid composition containing a milk protein mixture containing casein protein and whey protein, wherein the milky liquid composition comprises: Provided is a fatigue improvement method (excluding medical practice for humans) having a concentration of 4 to 8% by weight and a protein amount ratio of casein protein to whey protein (casein protein / whey protein) of 2 to 20. Here, the “medical action for humans” means an action that requires a doctor or the like to ingest (administer) a medicine to a human. The fatigue improving method of the present invention can be carried out according to the contents described in the present specification for the fatigue improving agent of the present invention.
本発明の一つの好ましい実施態様によれば、本発明の疲労改善方法において、前記乳タンパク質混合物が総タンパク質量で一食あたり０．０６ｇ以上／ｋｇ体重となるように摂取（投与）され、例えば、０．０６〜０．７ｇ／ｋｇ体重、０．０６〜０．６ｇ／ｋｇ体重、０．０６〜０．５ｇ／ｋｇ体重、０．０８〜０．４ｇ／ｋｇ体重、０．１〜０．４ｇ／ｋｇ体重となるように摂取（投与）される。ここで、対象の代表的な体重は、約６０ｋｇと見積もっている。ここで、本発明の疲労改善剤における、前記乳タンパク質混合物が総タンパク質量で一食あたり０．０６ｇ以上／ｋｇ体重であれば、本発明の疲労改善効果が奏され好ましい。 According to one preferred embodiment of the present invention, in the fatigue improving method of the present invention, the milk protein mixture is ingested (administered) so that the total protein amount is 0.06 g / kg body weight or more per meal, for example, 0.06-0.7 g / kg body weight, 0.06-0.6 g / kg body weight, 0.06-0.5 g / kg body weight, 0.08-0.4 g / kg body weight, 0.1-0. Ingested (administered) to 4 g / kg body weight. Here, the typical weight of the subject is estimated to be about 60 kg. Here, in the fatigue improving agent of the present invention, if the milk protein mixture is 0.06 g or more / kg body weight per serving in terms of total protein, the fatigue improving effect of the present invention is exhibited and preferable.
本発明の一つの好ましい実施態様によれば、本発明の疲労改善方法において、前記乳タンパク質混合物を総タンパク質量で一食あたり３ｇ以上となるように摂取させることができ、例えば、３〜４０ｇ、３〜２０ｇ、４〜２０ｇ、４〜１５ｇ、５〜１５ｇとなるように摂取させることができる。 According to one preferred embodiment of the present invention, in the fatigue improving method of the present invention, the milk protein mixture can be ingested so that the total protein amount is 3 g or more per serving, for example, 3 to 40 g, 3 -20 g, 4-20 g, 4-15 g, 5-15 g can be ingested.
本発明の一つの実施態様によれば、本発明の疲労改善方法において、前記乳タンパク質混合物を、疲労改善を必要とする対象に加温した液状形態で摂取させることができる。 According to one embodiment of the present invention, in the fatigue improvement method of the present invention, the milk protein mixture can be ingested in a heated liquid form to a subject in need of fatigue improvement.
本発明のさらに別の実施形態によれば、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を含む乳性液状組成物の疲労改善における使用であって、乳性液状組成物において、乳タンパク質混合物の濃度が４〜８重量％であり、かつホエイタンパク質に対するカゼインタンパク質のタンパク質量比（カゼインタンパク質／ホエイタンパク質）が２〜２０である使用が提供される。また、本発明のさらに別の実施形態によれば、カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物を含む乳性液状組成物の、疲労改善剤の製造における使用であって、乳性液状組成物において、乳タンパク質混合物の濃度が４〜８重量％であり、かつホエイタンパク質に対するカゼインタンパク質のタンパク質量比（カゼインタンパク質／ホエイタンパク質）が２〜２０である使用が提供される。ここで、「使用」とは、非治療的使用を意味し、医師が行う治療的使用は含まれない。 According to yet another embodiment of the present invention, the use of a milky liquid composition comprising a milk protein mixture comprising casein protein and whey protein in reducing fatigue, wherein in the milky liquid composition, Use is provided wherein the concentration is 4-8% by weight and the protein content ratio of casein protein to whey protein (casein protein / whey protein) is 2-20. According to still another embodiment of the present invention, a milky liquid composition comprising a milk protein mixture comprising casein protein and whey protein is used in the manufacture of a fatigue ameliorating agent, the milky liquid composition Provides a use wherein the concentration of the milk protein mixture is 4-8% by weight and the protein content ratio of casein protein to whey protein (casein protein / whey protein) is 2-20. Here, “use” means non-therapeutic use and does not include therapeutic use performed by a doctor.
本発明の一つの好ましい実施態様によれば、本発明の使用において、乳タンパク質混合物が総タンパク質量で一食あたり０．０６ｇ以上／ｋｇ体重となるように摂取（投与）され、例えば、０．０６〜０．７ｇ／ｋｇ体重、０．０６〜０．６ｇ／ｋｇ体重、０．０６〜０．５ｇ／ｋｇ体重、０．０８〜０．４ｇ／ｋｇ体重、０．１〜０．４ｇ／ｋｇ体重となるように摂取（投与）されてもよい。ここで、対象の代表的な体重は、約６０ｋｇと見積もっている。ここで、本発明の使用において、乳タンパク質混合物が総タンパク質量で一食あたり０．０６ｇ以上／ｋｇ体重であれば、本発明の疲労改善効果が奏され好ましい。 According to one preferred embodiment of the present invention, in the use of the present invention, the milk protein mixture is ingested (administered) so that the total protein amount is 0.06 g / kg body weight or more per serving, for example, 0.06 -0.7 g / kg body weight, 0.06-0.6 g / kg body weight, 0.06-0.5 g / kg body weight, 0.08-0.4 g / kg body weight, 0.1-0.4 g / kg You may ingest (administer) so that it may become a body weight. Here, the typical weight of the subject is estimated to be about 60 kg. Here, in the use of the present invention, if the milk protein mixture is 0.06 g or more / kg body weight per serving in terms of total protein, the fatigue improving effect of the present invention is exhibited, which is preferable.
本発明の一つの好ましい実施態様によれば、本発明の使用において、乳タンパク質混合物を総タンパク質量で一食あたり３ｇ以上となるように摂取させることができ、例えば、３〜４０ｇ、３〜２０ｇ、４〜２０ｇ、４〜１５ｇ、５〜１５ｇとなるように摂取させることができる。 According to one preferred embodiment of the present invention, in the use of the present invention, the milk protein mixture can be ingested so that the total protein amount is 3 g or more per meal, for example, 3 to 40 g, 3 to 20 g, It can be ingested so as to be 4 to 20 g, 4 to 15 g, and 5 to 15 g.
ところで、本発明の疲労改善剤は、非特許文献１で示された牛乳と比較して、１回（１日）の摂取量が少なく、また継続摂取を必要とする期間が短くても、十分な疲労改善効果が見られた。非特許文献１においては、１日５００ｍｌ〜１０００ｍｌの牛乳（カゼインタンパク質とホエイタンパク質とを含む乳タンパク質混合物が３．６重量％含有する乳性液状組成物ともいえる）を１６週間摂取という、多量かつ長期間の液体の摂取を必要としたが、本発明の疲労改善剤に対しては、１日あたり１００〜５００ｇ、１〜８週間の摂取で疲労改善の効果を奏することを見出した。 By the way, compared with the milk shown by the nonpatent literature 1, the fatigue improvement agent of this invention is sufficient even if there is little intake of 1 time (1 day) and the period which requires continuous intake is short. The fatigue improvement effect was seen. In Non-Patent Document 1, 500 ml to 1000 ml of milk (which can be said to be a milky liquid composition containing 3.6% by weight of a milk protein mixture containing casein protein and whey protein) per day for 16 weeks, Although long-term liquid intake was required, it was found that the fatigue-improving agent of the present invention has an effect of improving fatigue by ingesting 100 to 500 g per day for 1 to 8 weeks.
本発明の疲労改善剤は継続摂取することができる。継続摂取における、１回（１日）あたりの摂取量は、１日あたり、例えば、１００〜５００ｍｌ、１５０〜５００ｍｌ、２００〜５００ｍｌ、３００〜５００ｍｌ、３２０〜４８０ｍｌ、３４０〜４６０ｍｌ、３５０〜４５０ｍｌ、３６０〜４４０ｍｌ、３７０〜４３０ｍｌ、３８０〜４２０ｍｌである。ここで、本発明の疲労改善剤を１回（１日）あたり、１００ｇ以上摂取することで、本発明の効果を奏することができるため、好ましい。また、本発明の疲労改善剤を１回（１日）あたり、５００ｍｌ以下摂取することで、本発明の疲労改善剤を摂取することに負担がないため、好ましい。 The fatigue improving agent of the present invention can be taken continuously. In the continuous intake, the intake amount per time (daily) is, for example, 100 to 500 ml, 150 to 500 ml, 200 to 500 ml, 300 to 500 ml, 320 to 480 ml, 340 to 460 ml, 350 to 450 ml, 360-440 ml, 370-430 ml, 380-420 ml. Here, since the effect of this invention can be show | played by ingesting 100g or more of the fatigue | exhaustion improving agent of this invention per time (1 day), it is preferable. In addition, it is preferable to take 500 ml or less of the fatigue ameliorating agent of the present invention per time (per day) because there is no burden on ingesting the fatigue ameliorating agent of the present invention.
継続摂取における、継続期間は、例えば、１〜８週間、２〜８週間、２〜７週間、２〜６週間、２〜５週間、２〜４週間である。本発明の疲労改善剤を１週間以上継続摂取することで、本発明の効果をそうすることができるため、好ましい。また、本発明の疲労改善剤を８週間以下継続摂取することで、本発明の疲労改善剤を摂取することに負担がないため、好ましい。 The duration of continuous intake is, for example, 1-8 weeks, 2-8 weeks, 2-7 weeks, 2-6 weeks, 2-5 weeks, 2-4 weeks. It is preferable to continuously take the fatigue-improving agent of the present invention for one week or more because the effects of the present invention can be achieved. In addition, it is preferable to continuously take the fatigue improving agent of the present invention for 8 weeks or less because there is no burden in taking the fatigue improving agent of the present invention.
以下では、実施例を挙げて、本発明をさらに詳細に説明するが、本発明は、これにより限定されない。 Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited thereto.
［実施例１］
生乳（乳タンパク質３．３重量％、乳脂肪分３．８重量％、乳糖４．８重量％、灰分０．７重量％、水分８７．４重量％）に、乳タンパク質濃縮物（乳タンパク質８０重量％、乳糖６．５重量％）、脱脂粉乳（乳タンパク質３４重量％、乳脂肪分１重量％、乳糖５５重量％、灰分７重量％、水分６重量％）、水を混合し、乳タンパク質５．２５重量％、乳脂肪１．９５重量％、乳糖４．６５重量％となるよう加熱溶解した。これをプレート殺菌機で１４０℃５秒間の殺菌をし、２０ＭＰａの均質化処理（７０〜８０℃）をしてから、冷却したものを実施例１の疲労改善剤（乳タンパク質５．２５重量％、乳脂肪１．９５重量％、乳糖４．６５重量％、比重１．０３）とした。なお、ここで使用した乳タンパク質濃縮物は、脱脂乳を膜分離処理（ＵＦ処理、ＭＦ処理など）して、乳糖や灰分を除去し、カゼインタンパク質とホエイタンパク質とを主体として濃縮した、カゼインタンパク質とホエイタンパク質との混合物であり、その形態は、乾燥粉末である。そして、乳タンパク質濃縮物のタンパク質量比は、生乳（牛乳）と同様に、カゼインタンパク質：ホエイタンパク質＝約８：２である（山内邦男および横山健吉編、ミルク総合辞典参照）。[Example 1]
Milk protein concentrate (milk protein 80) is added to raw milk (milk protein 3.3 wt%, milk fat content 3.8 wt%, lactose 4.8 wt%, ash content 0.7 wt%, moisture 87.4 wt%). % Milk, lactose 6.5%), skim milk powder (milk protein 34% by weight, milk fat 1% by weight, lactose 55% by weight, ash 7% by weight, water 6% by weight), water and milk protein The mixture was dissolved by heating so that the amount was 5.25% by weight, milk fat 1.95% by weight, and lactose 4.65% by weight. This was sterilized at 140 ° C. for 5 seconds with a plate sterilizer, homogenized at 20 MPa (70-80 ° C.), and then cooled, the fatigue improving agent of Example 1 (milk protein 5.25% by weight) Milk fat 1.95% by weight, lactose 4.65% by weight, specific gravity 1.03). The milk protein concentrate used here is casein protein obtained by subjecting skim milk to membrane separation treatment (UF treatment, MF treatment, etc.), removing lactose and ash, and concentrating mainly on casein protein and whey protein. And a whey protein in the form of a dry powder. And the protein amount ratio of milk protein concentrate is casein protein: whey protein = about 8: 2, like raw milk (milk) (see Kunio Yamauchi and Kenkichi Yokoyama, Milk General Dictionary).
［試験例１］
以下の通り、実施例１の疲労改善剤による疲労改善効果を検証した。
（１）対象
空手競技者３２名とソフトテニス競技者１３名を対象とした。
そして、これらの対象者に実施例１の疲労改善剤４００ｍｌを４週間毎日で摂取させた。具体的には、空手やソフトテニスの練習がある日は、練習前に２００ｍｌ、練習後に２００ｍｌを、練習のない日は、朝に２００ｍｌ、夕方に２００ｍｌを摂取させた。
（２）疲労感の評価
ビジュアルアナログスケール（ＶＡＳ）を用いて、空手やソフトテニスの練習後の体全体の疲労感（自覚症状）を評価した。このＶＡＳ評価は、「何もできないほど疲れ切った最悪の感覚」と感じられる場合を０、「疲れを全く感じない最良の感覚」と感じられる場合を１００として、被験者のＶＡＳスコアを集計して行った。ＶＡＳ評価は、実施例１の疲労改善剤の摂取前、摂取２週間後、および摂取４週間後のそれぞれ練習後、練習翌朝に行った。[Test Example 1]
The fatigue improvement effect by the fatigue improving agent of Example 1 was verified as follows.
(1) Target The target was 32 karate athletes and 13 soft tennis athletes.
Then, these subjects were allowed to take 400 ml of the fatigue improving agent of Example 1 every day for 4 weeks. Specifically, when there was practice of karate and soft tennis, 200ml was taken before practice, 200ml after practice, and 200ml was taken in the morning and 200ml in the evening when there was no practice.
(2) Evaluation of Fatigue A visual analog scale (VAS) was used to evaluate fatigue (subjective symptoms) of the entire body after practicing karate and soft tennis. In this VAS evaluation, the VAS score of the subject was totaled by setting 0 as the case where it was felt as “the worst feeling exhausted so that nothing could be done” and 100 as the case where it was felt as “the best feeling without feeling tired at all”. went. The VAS evaluation was carried out in the morning following the practice, after each practice before intake, 2 weeks after intake, and 4 weeks after intake.
得られた数値から各試験群の平均値±標準誤差を求めた。統計処理は摂取２週間後、摂取４週間後において、疲労改善剤群の摂取前との間で対応のあるｔ検定を行った。有意水準は５％未満とした（ｐ＜０．０５）。空手競技者の結果を図１に、ソフトテニス競技者の結果を図２に示す。 The average value ± standard error of each test group was determined from the obtained numerical values. In statistical processing, t-tests corresponding to before intake of the fatigue ameliorating agent group were performed after 2 weeks of intake and 4 weeks after intake. The significance level was less than 5% (p <0.05). FIG. 1 shows the results of karate athletes, and FIG. 2 shows the results of soft tennis athletes.
実施例１の疲労改善剤の継続摂取によって、空手競技者、ソフトテニス競技者とも摂取前と比較して、体全体からくる疲労感が優位に抑制された。これらの結果より、実施例１の疲労改善剤は、継続摂取による効果が示唆された。 By continuous ingestion of the fatigue-improving agent of Example 1, the feeling of fatigue coming from the whole body was predominately suppressed compared to before ingestion for both karate athletes and soft tennis athletes. From these results, the fatigue-improving agent of Example 1 was suggested to have an effect of continuous intake.
Claims (11)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015031325 | 2015-02-20 | ||
| JP2015031325 | 2015-02-20 | ||
| PCT/JP2016/054237 WO2016133036A1 (en) | 2015-02-20 | 2016-02-15 | Fatigue ameliorating agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2016133036A1 true JPWO2016133036A1 (en) | 2017-12-07 |
Family
ID=56689363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017500660A Pending JPWO2016133036A1 (en) | 2015-02-20 | 2016-02-15 | Fatigue improver |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPWO2016133036A1 (en) |
| CN (1) | CN107249358A (en) |
| SG (1) | SG11201706794XA (en) |
| TW (1) | TW201635909A (en) |
| WO (1) | WO2016133036A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2018164251A1 (en) * | 2017-03-10 | 2020-01-09 | 株式会社明治 | Composition for improving physical strength |
| JP6749665B1 (en) * | 2019-07-18 | 2020-09-02 | 株式会社東洋新薬 | Oral composition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5405020B2 (en) * | 2005-08-18 | 2014-02-05 | 株式会社明治 | Carnitine recovery method |
| JP2010100551A (en) * | 2008-10-22 | 2010-05-06 | Theravalues Corp | Activator of nuclear receptors ppar alpha, ppar delta and rxr |
| FI124323B (en) * | 2011-02-18 | 2014-06-30 | Valio Oy | Milk-based product and process for its preparation |
-
2016
- 2016-02-15 WO PCT/JP2016/054237 patent/WO2016133036A1/en active Application Filing
- 2016-02-15 CN CN201680010211.0A patent/CN107249358A/en active Pending
- 2016-02-15 SG SG11201706794XA patent/SG11201706794XA/en unknown
- 2016-02-15 JP JP2017500660A patent/JPWO2016133036A1/en active Pending
- 2016-02-16 TW TW105104516A patent/TW201635909A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107249358A (en) | 2017-10-13 |
| SG11201706794XA (en) | 2017-10-30 |
| WO2016133036A1 (en) | 2016-08-25 |
| TW201635909A (en) | 2016-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009304238B2 (en) | Whey protein compositions, methods and uses | |
| WO2015037720A1 (en) | Muscle repair promoter | |
| JP6728071B2 (en) | Muscle synthesis promoter | |
| JP7108521B2 (en) | Composition for promoting an increase in the amount of BDNF in the body | |
| US20050112177A1 (en) | Nutritional supplement composition and method | |
| WO2017026429A1 (en) | Muscle synthesis promoting agent | |
| WO2016133036A1 (en) | Fatigue ameliorating agent | |
| US20060062827A1 (en) | Nutritional supplement composition and method | |
| JP6037595B2 (en) | Satiety induction composition and method for producing the same | |
| JP6430386B2 (en) | Body moisture retention agent | |
| EP2956015B1 (en) | Method for restoring and/or maintaining a positive net protein balance in a child | |
| WO2017146141A1 (en) | Rehydration agent | |
| WO2018123873A1 (en) | Composition for promoting perspiration | |
| WO2018164251A1 (en) | Composition for improving physical strength | |
| Lochinbek et al. | Positive and negative sides of cow, goat and sheep milk | |
| Najmitdinova | Scientific study of the chemical composition of dairy products | |
| AU2014253468B2 (en) | Whey protein compositions, methods and uses | |
| Onur Oral et al. | MILK: A RICH NUTRITIONAL SOURCE FOR ATHLETES/SÜT: SPORCULAR IÇIN BIR ZENGIN BESLENME KAYNAGI | |
| BR102016018766A2 (en) | MUSHROOM ADDITIONAL Yoghurt Production | |
| Henry et al. | Nutrition support |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171024 |
|
| AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20171024 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190107 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200120 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200319 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200831 |